



Solenio Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease

September 19, 2018

REDWOOD CITY, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Solenio Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will conduct one-on-one investor meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease, being held September 26-27, 2018, in New York, NY.

About Solenio Therapeutics, Inc.

Solenio is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, DCCR, a once-daily oral tablet for the treatment of PWS, is currently being evaluated in a Phase III clinical development program.

For more information, please visit www.solenio.life.

CONTACT:

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578



Source: Solenio Therapeutics